Sanara MedTech Smashes Earnings, Eyes Surgical Pure-Play Future

Sanara MedTechs 2025 earnings report is a standout, with net revenue soaring to $103.1 million, a 19% increase from the previous year. The company maintained a steady field sales team of 40 reps, while expanding distributors to over 450, reaching 1,450 facilities, and growing their surgeon base across various specialties. The fourth quarter saw a 5% year-over-year revenue increase, adjusted for last years hurricane boost. Sanara successfully wound down the Tissue Health Plus project under budget and shifted focus to surgical products. Key achievements include BIASURGE securing a Vizient innovative tech contract, ALLOCYTE Plus excelling in spine fusion trials, and a growing patent portfolio. Looking ahead, Sanara reaffirmed 2026 guidance of $116-$121 million, with a commercial push, sales team hires, R&D for evidence and IP, and the launch of OsStic bone adhesive in Q1 2027. Sanara is now a lean surgical pure-play with anchor products targeting billions in wounds, strong margins, and momentum for future cash flow and profits. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/3236d402f209bde3